Methods of preventing tissue damage associated with decreased blood flow by administration of AICA riboside compounds
US5817640A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 16, 1995 |
| Grant date | Oct 6, 1998 |
| Priority date | — |
| Expiry date | May 16, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/975
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of preventing tissue damage associated with decreased blood flow in a human by administering AICA riboside or a prodrug thereof in an amount which provides a blood plasma concentration of between 1 .mu.g/ml and 20 .mu.g/ml of AICA riboside for a time sufficient to reduce the risk of said tissue damage in said human. Methods of preventing an adverse clinical outcome, such as an adverse cardiovascular and/or cerebrovascular event, in a patient at risk for such outcome by administering AICA riboside or a prodrug thereof in an amount which provides a blood plasma concentration of between 1 .mu.g/ml and 20 .mu.g/ml of AICA riboside for a time sufficient to reduce the risk for said patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.